WINTON GROUP Ltd Invests $6.90 Million in Organon & Co. $OGN

WINTON GROUP Ltd acquired a new stake in shares of Organon & Co. (NYSE:OGN) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 509,862 shares of the company’s stock, valued at approximately $6,904,000. WINTON GROUP Ltd owned about 0.19% of Organon & Co. at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allied Private Wealth LLC purchased a new stake in Organon & Co. in the second quarter valued at about $33,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Organon & Co. during the fourth quarter worth about $44,000. Kestra Advisory Services LLC acquired a new position in shares of Organon & Co. during the fourth quarter valued at about $47,000. WNY Asset Management LLC purchased a new position in shares of Organon & Co. in the 1st quarter valued at approximately $64,000. Finally, Empowered Funds LLC acquired a new stake in Organon & Co. in the 4th quarter worth approximately $74,000. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. Five equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Stock Performance

OGN opened at $13.69 on Thursday. The company has a current ratio of 1.95, a quick ratio of 1.44 and a debt-to-equity ratio of 8.43. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.78. The firm has a 50 day moving average of $13.63 and a two-hundred day moving average of $11.47. The firm has a market capitalization of $3.59 billion, a PE ratio of 17.77, a P/E/G ratio of 1.27 and a beta of 1.52.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Organon & Co.’s dividend payout ratio is presently 10.39%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.